Jade Biosciences Inc JBIO
$19.75
▼ -1.25%
($-0.25)
🗓️ Earnings Next Week
Open
$20.00
Prev Close
$20.00
Day Range
$18.64 – $20.04
52W Range
$6.67 – $28.00
Market Cap
$1.20B
Beta
1.42
EPS (TTM)
$-3.06
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-06-30 |
| Shares Out. | 60,850,000 |
| Website | jadebiosciences.com/ ↗ |
| Phone | 17813123013 |
| Employees | 55 |
| Net Income | -$40.4M |
| Free Cash Flow | -$101.7M |
| Total Assets | $319.4M |
| Total Liabilities | $23.0M |
| Equity | $296.5M |
About Jade Biosciences Inc
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
Jade Biosciences Inc is a publicly traded company under the ticker symbol JBIO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
17 analysts (2026-07-01)